Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Imiglucerase-Treated Italian Patients with Gaucher Disease Type 1 or Type 3 had the following Long-term Bone Outcomes: A Sub-study from the Global Cooperative Gaucher Gathering (ICGG) Gaucher Vault

Daou Abdlkri

A rare condition known to cause skeletal symptoms is Gaucher disease. It can progress to aseptic bone necrosis and pathological fractures in the advanced stage. Although enzymatic replacement therapy (ERT) has significantly improved a patient’s quality of life, it has not prevented complications related to the bone. There are very few publications in the literature that have discussed the surgical management of this disorder. The way these patients are handled in orthopedic surgery is very specific.

Most patients with Gaucher illness have moderate and frequently debilitating skeletal indications. The phenotypic diversity of Gaucher disease is well-known, and there are no consistent genotype-phenotype correlations. In Argentina, a public cooperative gathering, Grupo Argentino de Diagnóstico tratamiento de la enfermedad de Gaucher, GADTEG, portrayed consistently extreme sort Gaucher illness signs giving in youth a huge weight of irreversible skeletal sickness. Here utilizing Long-Read Single Atom Ongoing (SMRT) Sequencing of the GBA locus, we show that the RecNciI allele is profoundly common and is related to serious skeletal appearances with beginning in adolescence or in youthful grown-ups. In addition, we described a novel, previously unknown GBA variants.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié.